Loading…
Loading…
Howard Marks hunts dislocation. His latest Oaktree 13F reveals five common-stock equity positions that look nothing like a bull-market portfolio: a leveraged turbo maker, the largest US gas producer bleeding YTD, a gold miner that just gave back a fifth of its price in three months, a tanker riding a geopolitical spike, and a specialty pharma with negative book value.
Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for INDV and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.